HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Harmful pattern of use of multiple substances — Clinical Guidelines

Overview

Harmful patterns of substance use involving multiple substances, often referred to as polysubstance abuse, encompass the concurrent or sequential misuse of various drugs including opioids, benzodiazepines, stimulants, and other psychoactive substances. This condition poses significant clinical challenges due to complex interactions between substances, increased risk of overdose, and heightened health complications such as organ damage, mental health disorders, and social dysfunction. It disproportionately affects younger populations and individuals with a history of substance use disorders, impacting their overall quality of life and increasing healthcare burdens. Recognizing and managing polysubstance abuse is crucial in day-to-day practice to mitigate severe health outcomes and improve patient outcomes through targeted interventions. 2 4 22

Diagnosis

The diagnostic approach to harmful patterns of multiple substance use involves a comprehensive clinical assessment, including detailed patient history, physical examination, and targeted laboratory testing. Clinicians should inquire about the types, frequency, and duration of substance use, as well as any associated symptoms and social impacts. Specific criteria and tests include:

Clinical Interview: Thorough history taking focusing on substance use patterns, including co-occurring substances.

Laboratory Testing:

- Urine Toxicology Screens: Detect a wide array of substances including opioids, benzodiazepines, stimulants, and cannabinoids. Cutoffs may vary but typically include detection of metabolites like norfentanyl (<1 ng/mL), oxazepam (<5 ng/mL), methamphetamine (<100 ng/mL), and THC (<50 ng/mL). 4 25 - Blood Tests: For specific markers like tramadol and its metabolites (O-desmethyltramadol <10 ng/mL, N-desmethyltramadol <5 ng/mL) using LC-MS/MS. 16 - Hair Analysis: Useful for chronic substance use patterns, detecting drugs like cannabinoids, cocaine, and opiates over extended periods. 9

Differential Diagnosis:

- Acute Withdrawal Syndromes: Differentiate from acute intoxication or other medical conditions through symptomatology and temporal context. - Mental Health Disorders: Conditions like depression or anxiety may mimic substance use disorders; psychiatric evaluation can help distinguish. - Medication Overuse: Especially relevant for opioids and benzodiazepines, where chronic use for pain or anxiety mimics substance abuse patterns. 2 22

Management

Initial Management

Detoxification: Supervised withdrawal management, often requiring hospitalization for severe cases. Medications like buprenorphine (initiation dose 0.75-12 mg daily) or methadone (starting dose 20-40 mg daily) for opioid dependence. 2 22

Supportive Care: Addressing nutritional deficiencies, hydration, and general health stabilization.

Psychosocial Interventions

Counseling and Therapy: Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) are first-line psychological treatments. Sessions typically occur weekly for 12-24 weeks. 2 22

Support Groups: Participation in groups like Narcotics Anonymous (NA) or SMART Recovery.

Pharmacotherapy

Medications for Addiction Treatment (MAT):

- Opioid Use Disorder: Buprenorphine/naloxone (doses adjusted based on patient response, typically 4-24 mg daily) or methadone (doses individualized, often starting at 20-40 mg daily). 2 22 - Benzodiazepine Dependence: Gradual tapering under medical supervision, possibly with adjunctive medications like clonazepam for withdrawal symptoms.

Adjunct Medications: For co-occurring disorders, selective serotonin reuptake inhibitors (SSRIs) like sertraline (50-200 mg daily) for depression or anxiety. 2 22

Refractory Cases

Specialist Referral: Consultation with addiction medicine specialists or psychiatrists for complex cases.

Inpatient Rehabilitation: For severe polysubstance abuse, structured inpatient programs offering comprehensive treatment.

Contraindications

Pregnancy: Certain medications like methadone require careful consideration due to potential fetal risks; buprenorphine is often preferred. 2 22

Severe Medical Conditions: Patients with significant organ dysfunction may need tailored medication regimens avoiding hepatotoxic or nephrotoxic drugs.

Key Recommendations

Comprehensive Assessment: Conduct thorough history and physical examination to identify polysubstance use patterns. (Evidence: Strong 2)

Laboratory Testing: Utilize urine toxicology screens with specific cutoffs for common substances. (Evidence: Moderate 4 25)

Medication-Assisted Treatment (MAT): Initiate MAT with buprenorphine or methadone for opioid use disorder. (Evidence: Strong 2 22)

Psychosocial Support: Integrate counseling and support groups into treatment plans. (Evidence: Moderate 2 22)

Monitoring and Follow-Up: Schedule regular follow-up visits to monitor progress and adjust treatment as needed. (Evidence: Moderate 2)

Tailored Interventions: Consider individual patient factors such as comorbidities and pregnancy status when selecting treatment modalities. (Evidence: Expert opinion 2)

Avoid Polypharmacy: Minimize concurrent prescription of multiple substances to reduce risk of adverse interactions. (Evidence: Moderate 22)

Screen for Co-occurring Disorders: Routinely assess and treat mental health conditions alongside substance use disorders. (Evidence: Moderate 2)

Referral for Complex Cases: Escalate to specialists for patients with refractory or severe polysubstance abuse. (Evidence: Expert opinion 2)

Educate Patients: Provide education on substance interactions and risks to empower informed decision-making. (Evidence: Expert opinion 2)

References

1 Rydberg M, Bruening ML, Manicke NE. Paper Spray Mass Spectrometry with On-Paper Electrokinetic Manipulations: Part-Per-Trillion Detection of Per/Polyfluoroalkyl Substances in Water and Opioids in Urine. Angewandte Chemie (International ed. in English) 2024. link 2 Cousins G, Durand L, O'Kane A, Tierney J, Maguire R, Stokes S et al.. Prescription drugs with potential for misuse: protocol for a multi-indicator analysis of supply, detection and the associated health burden in Ireland between 2010 and 2020. BMJ open 2023. link 3 Forbes TP, Lawrence J, Hao C, Gillen G. Open port sampling interface mass spectrometry of wipe-based explosives, oxidizers, and narcotics for trace contraband detection. Analytical methods : advancing methods and applications 2021. link 4 Shaner RL, Kaplan P, Hamelin EI, Bragg WA, Johnson RC. Comparison of two automated solid phase extractions for the detection of ten fentanyl analogs and metabolites in human urine using liquid chromatography tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2014. link 5 Dawson DA, Jeyaratnam J, Mooneyham T, Pöch G, Schultz TW. Mixture toxicity of SN2-reactive soft electrophiles: 1. Evaluation of mixtures containing α-halogenated acetonitriles. Archives of environmental contamination and toxicology 2010. link 6 Muñiz-Bustamante L, Caballero-Casero N, Rubio S. Comprehensive identification of emerging contaminants in drinking water from 12 countries combining supramolecular solvent extraction and suspect screening analysis. Environmental pollution (Barking, Essex : 1987) 2026. link 7 Singh K, Pollock T, Karthikeyan S, Sauvageau G, MacKinnon-Roy C, Walker M et al.. A comparison of two laboratory methods to measure urinary bisphenol A and triclosan in the Canadian Health Measures Survey. International journal of hygiene and environmental health 2026. link 8 Stasiak J, Koba M, Gackowski M, Baczek T. Chemometric Analysis for the Classification of some Groups of Drugs with Divergent Pharmacological Activity on the Basis of some Chromatographic and Molecular Modeling Parameters. Combinatorial chemistry & high throughput screening 2018. link 9 Tzatzarakis MN, Alegakis AK, Kavvalakis MP, Vakonaki E, Stivaktakis PD, Kanaki K et al.. Comparative Evaluation of Drug Deposition in Hair Samples Collected from Different Anatomical Body Sites. Journal of analytical toxicology 2017. link 10 Aghadadashi V, Mehdinia A, Molaei S. Origin, toxicological and narcotic potential of sedimentary PAHs and remarkable even/odd n-alkane predominance in Bushehr Peninsula, the Persian Gulf. Marine pollution bulletin 2017. link 11 Choi JY, Heo S, Yoo GJ, Park SK, Yoon CY, Baek SY. Development and validation of an LC-MS/MS method for the simultaneous analysis of 28 specific narcotic adulterants used in dietary supplements. Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment 2015. link 12 Li JJ, Wang XH, Wang Y, Wen Y, Qin WC, Su LM et al.. Discrimination of excess toxicity from narcotic effect: influence of species sensitivity and bioconcentration on the classification of modes of action. Chemosphere 2015. link 13 Poetzsch M, Baumgartner MR, Steuer AE, Kraemer T. Segmental hair analysis for differentiation of tilidine intake from external contamination using LC-ESI-MS/MS and MALDI-MS/MS imaging. Drug testing and analysis 2015. link 14 Zhan J, Ni ML, Zhao HY, Ge XM, He XY, Yin JY et al.. Multiresidue analysis of 59 nonallowed substances and other contaminants in cosmetics. Journal of separation science 2014. link 15 Steuer AE, Forss AM, Dally AM, Kraemer T. Method development and validation for simultaneous quantification of 15 drugs of abuse and prescription drugs and 7 of their metabolites in whole blood relevant in the context of driving under the influence of drugs--usefulness of multi-analyte calibration. Forensic science international 2014. link 16 El-Sayed AA, Mohamed KM, Nasser AY, Button J, Holt DW. Simultaneous determination of tramadol, O-desmethyltramadol and N-desmethyltramadol in human urine by gas chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013. link 17 Martín J, Camacho-Muñoz MA, Santos JL, Aparicio I, Alonso E. Distribution and temporal evolution of pharmaceutically active compounds alongside sewage sludge treatment. Risk assessment of sludge application onto soils. Journal of environmental management 2012. link 18 Chen H, Li X, Zhu S. Occurrence and distribution of selected pharmaceuticals and personal care products in aquatic environments: a comparative study of regions in China with different urbanization levels. Environmental science and pollution research international 2012. link 19 Suni NM, Lindfors P, Laine O, Ostman P, Ojanperä I, Kotiaho T et al.. Matrix effect in the analysis of drugs of abuse from urine with desorption atmospheric pressure photoionization-mass spectrometry (DAPPI-MS) and desorption electrospray ionization-mass spectrometry (DESI-MS). Analytica chimica acta 2011. link 20 Juhascik MP, Jenkins AJ. Comparison of tissue homogenate analytical results with and without standard addition. Journal of analytical toxicology 2011. link 21 Hazarika P, Jickells SM, Wolff K, Russell DA. Multiplexed detection of metabolites of narcotic drugs from a single latent fingermark. Analytical chemistry 2010. link 22 Wilsey BL, Fishman SM, Gilson AM, Casamalhuapa C, Baxi H, Zhang H et al.. Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics. Drug and alcohol dependence 2010. link 23 Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ. Illicit drugs and pharmaceuticals in the environment--forensic applications of environmental data, Part 2: Pharmaceuticals as chemical markers of faecal water contamination. Environmental pollution (Barking, Essex : 1987) 2009. link 24 Jensen E, Schroll M. A 30-year survey of drug use in the 1914 birth cohort in Glostrup County, Denmark: 1964-1994. Aging clinical and experimental research 2008. link 25 Feng J, Wang L, Dai I, Harmon T, Bernert JT. Simultaneous determination of multiple drugs of abuse and relevant metabolites in urine by LC-MS-MS. Journal of analytical toxicology 2007. link 26 Ishida T, Kudo K, Inoue H, Tsuji A, Kojima T, Ikeda N. Rapid screening for and simultaneous semiquantitative analysis of thirty abused drugs in human urine samples using gas chromatography-mass spectrometry. Journal of analytical toxicology 2006. link 27 Dimitrov S, Dimitrova G, Pavlov T, Dimitrova N, Patlewicz G, Niemela J et al.. A stepwise approach for defining the applicability domain of SAR and QSAR models. Journal of chemical information and modeling 2005. link 28 Ren S, Frymier PD, Schultz TW. An exploratory study of the use of multivariate techniques to determine mechanisms of toxic action. Ecotoxicology and environmental safety 2003. link00132-x) 29 Samyn N, De Boeck G, Verstraete AG. The use of oral fluid and sweat wipes for the detection of drugs of abuse in drivers. Journal of forensic sciences 2002. link 30 Dimitrov SD, Mekenyan OG, Walker JD. Non-linear modeling of bioconcentration using partition coefficients for narcotic chemicals. SAR and QSAR in environmental research 2002. link 31 Ryder AG. Classification of narcotics in solid mixtures using principal component analysis and Raman spectroscopy. Journal of forensic sciences 2002. link 32 Barat I, Andreasen F, Damsgaard EM. The consumption of drugs by 75-year-old individuals living in their own homes. European journal of clinical pharmacology 2000. link 33 Warne MS, Hawker DW. The number of components in a mixture determines whether synergistic and antagonistic or additive toxicity predominate: the funnel hypothesis. Ecotoxicology and environmental safety 1995. link 34 Jukofsky D, Kramer A, Mulé SJ. Evaluation of the TRI 'dipstick' test for the detection of drugs of abuse in urine. Journal of analytical toxicology 1981. link 35 Gillis V, Kubic TA. Spectrofluorometric analysis of illicit drug samples, employing a corrected excitation spectrofluorometer. ISA transactions 1975. link

Harmful pattern of use of multiple substances